What Covaxin-Maker Bharat Biotech Said After WHO Approved India-Made Jab
NDTV
The Emergency Use Listing will help countries expedite their regulatory approval processes to introduce and administer Covaxin, Bharat Biotech said.
The World Health organisation's approval of Covaxin will expedite global access and availability of the first India-made vaccine against coronavirus worldwide, its manufacturer Bharat Biotech said in a statement.
In a statement released this evening, the pharma firm said that the Emergency Use Listing will help countries expedite their regulatory approval processes to introduce and administer India's indigenously made COVID-19 vaccine. It will also allow procurement of the vaccine by UNICEF, Pan-American Health Organization (PAHO), and the GAVI COVAX facility for distribution globally and ensure equitable access, it added.
"Validation by WHO is a very significant step towards ensuring global access to India's widely administered, safe, and efficacious Covaxin. As an organization, we have focused on maintaining stringent quality and safety standards that meet rigorous assessment, and scientific standards established by WHO, as a result, many of our vaccines have received WHO prequalification," said Dr Krishna Ella, Chairman and Managing Director of Bharat Biotech.
"The EUL authorisation for Covaxin will enable us to contribute to accelerating the equitable access of Covid-19 vaccine, and the access to our vaccine globally thereby addressing the current public health emergency."
